Galmed Pharmaceuticals (GLMD) Capital Expenditures (2013 - 2023)
Galmed Pharmaceuticals (GLMD) posted quarterly Capital Expenditures of -$4000.0 for Q1 2023, down 300.0% year-over-year from $2000.0 in Q1 2022, and down 157.14% quarter-over-quarter from $7000.0 in Q4 2022.
Galmed Pharmaceuticals (GLMD) Capital Expenditures (2013 - 2023) Analysis & Trends
Galmed Pharmaceuticals' Capital Expenditures history runs 11 years deep, the most recent figure standing at -$4000.0 for Q1 2023.
- In Q1 2023, Capital Expenditures fell 300.0% year-over-year to -$4000.0; the TTM figure through Mar 2023 stood at $1000.0 (down 90.91% YoY), while the FY2025 annual figure was -$7000.0, down 600.0% from the prior year.
- Capital Expenditures for Q1 2023 stood at -$4000.0, down from $7000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $77000.0 in Q4 2020, with the low at -$28000.0 in Q3 2020.
- The 5-year median for Capital Expenditures is -$2000.0 (2021), against an average of $3692.3.
- Peak annual rise in Capital Expenditures reached 2666.67% in 2020, while the deepest fall reached 460.0% in 2020.
- Galmed Pharmaceuticals' Capital Expenditures stood at -$3000.0 in 2019, then jumped by 2666.67% to $77000.0 in 2020, then slumped by 72.73% to $21000.0 in 2021, then slumped by 66.67% to $7000.0 in 2022, then slumped by 157.14% to -$4000.0 in 2023.
- Business Quant data shows GLMD's Capital Expenditures at -$4000.0 in Q1 2023, $7000.0 in Q4 2022, and -$2000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Dec 31, 2022 | 7,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | 21,000.00 |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -7,000.00 |
| Jun 30, 2021 | -7,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Dec 31, 2020 | 77,000.00 |
| Dec 31, 2020 | 77,000.00 |
| Sep 30, 2020 | -28,000.00 |
| Sep 30, 2020 | -28,000.00 |